scholarly journals The Assessment of Red Blood Cell Distribution Width, Platelet Parameters and Inflammatory Markers in Patients on Antıpsoriasis Therapy

Acta Medica ◽  
2019 ◽  
Vol 50 (2) ◽  
pp. 39-46
Author(s):  
Osman Murat Kalaycı ◽  
Duygu Gülseren ◽  
Tülin Akan

Aims: Psoriasis is an inflammatory skin disease with several comorbidities. We aimed to evaluate red blood cell distribution width (RDW), platelet parameters and inflammatory markers in patients on antipsoriasis therapies. Methods: 94 psoriasis patients and 74 healthy controls were prospectively analyzed. Before and after 8 weeks of different therapies (calcipotriol+clobetasol propionate; narrow-band UVB; combined narrow-band UVB and acitretin; infliximab and adalimumab), red blood cell distribution width (RDW), platelet parameters, high sensitivity C reactive protein (hs-CRP), and erythrocyte sedimentation rate (ESR) levels were measured. Lipid profile and fasting blood glucose tests were also performed prior the treatment. Psoriasis severity and area index (PASI) and body mass index (BMI) were calculated for each patient. Results: RDW, hs-CRP, triglyceride, total cholesterol levels and BMI were higher in patients than in controls (p<0.05, for all four). No significant differences were observed in RDW, platelet parameters, hs-CRP and ESR levels after all therapies (p>0.05, for all). RDW was not correlated with PASI (p>0.05). Conclusion: Psoriasis patients should be screened for dyslipidemia and obesity. Antipsoriasis therapies do not have any effect on inflammatory markers. Further studies are needed to elucidate the use of RDW and platelet parameters as an inflammatory marker in psoriasis.

2021 ◽  
Vol 10 (2) ◽  
pp. 286
Author(s):  
Angelo Zinellu ◽  
Arduino A. Mangoni

The identification of biomarkers predicting disease severity and outcomes is the focus of intense research in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 infection). Ideally, such biomarkers should be easily derivable from routine tests. We conducted a systematic review and meta-analysis of the predictive role of the red blood cell distribution width (RDW), a routine hematological test, in patients with SARS-CoV-2 infection. We searched the electronic databases PubMed, Web of Science and Scopus, from January 2020 to November 2020, for studies reporting data on the RDW and coronavirus disease 2019 (COVID-19) severity, defined as severe illness or admission to the intensive care unit (ICU), and mortality. Eleven studies in 4901 COVID-19 patients were selected for the meta-analysis. Pooled results showed that the RDW values were significantly higher in patients with severe disease and non-survivors (standard mean difference, SMD = 0.56, 95% CI 0.31 to 0.81, p < 0.001). Heterogeneity between studies was extreme (I2 = 80.6%; p < 0.001). In sensitivity analysis, the effect size was not modified when each study was in turn removed (effect size range, between 0.47 and 0.63). The Begg’s (p = 0.53) and Egger’s tests (p = 0.52) showed no evidence of publication bias. No significant correlations were observed between SMD and age, gender, whole blood count, end point, study geographic area, or design. Our meta-analysis showed that higher RDW values are significantly associated with COVID-19 severity and mortality. This routine parameter might assist with early risk stratification in patients with SARS-CoV-2 infection.


2013 ◽  
Vol 275 (1) ◽  
pp. 84-92 ◽  
Author(s):  
S. Adamsson Eryd ◽  
Y. Borné ◽  
O. Melander ◽  
M. Persson ◽  
J. G. Smith ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document